| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Gossamer Bio, Inc.$0.17
-0.01 (-3.71%)
D 37Pipeline Score Fair Value Pharma · Commercial
Market Cap
49.31 M
EPS
-0.79
P/E Ratio
-
Value Trade
2.31 M
SEC Financials
Q1 2026Dilution Risk
Revenue
16.95 M
R&D Expenses
43.08 M
Operating CF
-38.72 M
Total Assets
128.90 M
Total Liabilities
290.38 M
Equity
-161.48 M
D/E Ratio
12,345
-36.33 %
Week
-43.25 %
1 Month
-90 %
3 Month
-93.24 %
6 Month
-97.75 %
5 Year
-98.89 %
All Time
Cash Data
Cash Position
99.22 M
Monthly Burn
12.91 M
Runway
6.1 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
12.92 M
52 Week Range
0.16 - 3.87
% held by Insiders
8.1 %
% held by Institutions
61.33 %
Enterprise Value
153.03 M
Total Shares
231.46 M
Short %
12.51 %
Float Shares
213.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gossamer Bio, Inc.
174Total events
1Upcoming
43Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 1
Event history 173
Jun 2, 2026
◆Quarterly UpdateCorporate
Extension of early tender date for exchange offer and consent solicitation for convertible notes
Jun 2026
◆FDA Feedback ReceivedSeralutinibFDA Meeting
Engagement with FDA to discuss PROSERA results and potential development path
pulmonary arterial hypertension (PAH)source ↗
Jun 2026
◆Type C MeetingSeralutinibFDA Meeting
Planned Type C meeting with FDA to discuss PROSERA data and regulatory path
pulmonary arterial hypertension (PAH)source ↗
May 18, 2026
Mar 18, 2026
▼Topline ReadoutSeralutinibClinical Data
PROSERA Phase 3 topline results: narrowly missed primary endpoint
pulmonary arterial hypertension (PAH)source ↗
Mar 18, 2026
▼Enrollment PausedSeralutinibTrial
Enrollment paused in Phase 3 SERANATA Study in PH-ILD
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
Mar 18, 2026
Mar 17, 2026
▼Enrollment PausedSeralutinibTrial
Enrollment paused in Phase 3 SERANATA study in PH-ILD
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
Mar 17, 2026
Mar 2026
◆Additional DataSeralutinibClinical Data
PROSERA CT functional respiratory imaging substudy results expected
pulmonary arterial hypertensionsource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $87M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.8x
rNPV / MCap Top 52%
Micro Cap (rank 438 of 911)
Percentile RankGossamer Bio, Inc. faces pipeline headwinds (37/100), with $1.5B risk-adjusted pipeline value, led by Seralutinib in Pulmonary Arterial Hypertension (Phase 3), across $51B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seralutinib Small molecule | Pulmonary Arterial Hypertension | Phase 3 | NCT06274801 | 48% | $836M | ACTIVE NOT_RECRUITING | 706 | VERY_FAST | C (40) | Dec 1, 2026 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Gossamer Bio | — | Phase 3 | 2026-05-07 | failed to meet the primary endpoint | GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt Read More | |
Gossamer Bio | — | Phase 3 | 2026-05-07 | failed to meet the primary endpoint | GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt Read More | |
Gossamer Bio | — | Phase 3 | 2026-05-07 | failed to meet the primary endpoint | GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GOSS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GOSS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GOSSGossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Gossamer Bio, Inc. has announced the conversion rate for its 7.50% convertible senior secured first lien notes due in 2030, along with the exercise price for purchase warrants. This announcement is part of the company's ongoing financial strategy. Further details regarding the implications of these changes were not provided in the article.
Read more →GOSS▲ +6.7%on this news
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the final tender results for its exchange offer and consent solicitation concerning existing convertible notes. The announcement provides details about the completion of the exchange offer, but lacks specific financial figures or implications for stakeholders. The company aims to streamline its capital structure through this initiative.
Read more →GOSS▼ -8.7%on this newsshared move
For Patients: Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial
The article discusses the results of the Phase 3 PROSERA trial for Seralutinib, a treatment for pulmonary arterial hypertension (PAH). The trial's findings indicate positive outcomes, suggesting that Seralutinib may be an effective option for patients suffering from this condition. The article emphasizes the importance of these results for future treatment pathways.
Read more →GOSS▲ +9.2%on this newsshared move
Understanding the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis
The article discusses a retrospective analysis of the diagnostic journey for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). It highlights the complexities and challenges faced by patients in obtaining a diagnosis. The analysis is based on U.S. claims data, providing insights into the healthcare experiences of these patients.
Read more →GOSS▲ +9.2%on this newsshared move
Understanding Patient Experiences, Challenges, and Emotions During Diagnosis of PH-ILD: A Qualitative Study
The article discusses a qualitative study focused on patient experiences, challenges, and emotions during the diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD). It highlights the importance of understanding these patient perspectives to improve care and treatment outcomes. The study aims to shed light on the emotional and practical challenges faced by patients.
Read more →GOSS▲ +9.2%on this newsshared move
Examining Undertreatment and Delays in Therapy for Pulmonary Arterial Hypertension: A Real-world Patient Journey Study from the US
The article discusses a study on the undertreatment and delays in therapy for patients with pulmonary arterial hypertension (PAH) in the US. It highlights the challenges faced by patients in accessing timely treatment. The study aims to shed light on the real-world patient journey and the implications for healthcare providers and policymakers.
Read more →GOSS▲ +9.2%on this newsshared move
Advancing Careers and Leadership in Pulmonary Hypertension: Key Insights From Pulmonary Hypertension Clinicians
The article discusses the advancements in careers and leadership within the field of pulmonary hypertension, highlighting insights from clinicians. It emphasizes the importance of collaboration and management in enhancing patient care and treatment options. The focus is on the role of Seralutinib in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read more →GOSS▼ -5.9%on this news· ran to -17% by day 3
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the early tender results and early settlement for its exchange offer and consent solicitation related to existing convertible notes. The announcement indicates a strategic move by the company but lacks detailed information on the implications or outcomes of the offer.
Read more →GOSSGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced an extension of the early tender date for its exchange offer and consent solicitation related to existing convertible notes. This decision is part of the company's ongoing financial strategies. Further details regarding the implications of this extension were not provided in the announcement.
Read more →GOSS▼ -43.3%on this news
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Gossamer Bio, Inc. has announced an exchange offer and consent solicitation aimed at eliminating over $120 million of debt. This initiative has received support from existing noteholders, indicating confidence in the company's financial strategy. The move is part of Gossamer's efforts to strengthen its balance sheet and improve financial stability.
Read more →GOSS▼ -43.3%on this news
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio has released its financial results for the first quarter of 2026 along with a business update. The details of the financial performance and any strategic plans or developments were not disclosed in the article. Further insights into the company's direction or upcoming initiatives were also not provided.
Read more →GOSS▼ -43.3%on this newsshared move
Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial
The article discusses the results of the Phase 3 PROSERA trial for Seralutinib, a treatment for pulmonary arterial hypertension (PAH). The trial indicates that Seralutinib may effectively improve outcomes for patients suffering from this condition. The findings contribute to the ongoing research and development of therapies for PAH.
Read more →GOSSGossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
Gossamer Bio has scheduled the announcement of its first quarter 2026 financial results. The company will host a conference call and webcast on May 18, 2026, to discuss the results. Further details regarding the financial performance and future outlook may be shared during this event.
Read more →GOSSGOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt
Gossamer Bio, Inc. is facing a securities class action lawsuit after its Phase 3 PROSERA study failed to meet primary endpoints, resulting in an 80% drop in share price. CEO Faheem Hasnain is named as a defendant, accused of concealing material risks associated with the trial. Investors are alerted to the June 1, 2026 deadline for lead plaintiff applications.
Read more →GOSSA Real-World Mixed Methods Analysis of Undertreatment and Delays in Therapy Escalation in Pulmonary Arterial Hypertension in the US
The article discusses a mixed methods analysis focused on the undertreatment and delays in therapy escalation for patients with Pulmonary Arterial Hypertension (PAH) in the United States. It highlights the challenges faced in managing PAH effectively, emphasizing the need for improved treatment strategies. The analysis aims to shed light on real-world issues affecting patient care in this condition.
Read more →GOSS▼ -8%on this news· ran to -21% by day 3
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio announced its financial results for Q4 and full year 2025, highlighting a focus on the PROSERA Phase 3 trial results. The company is engaging with the FDA while pausing enrollment in the SERANATA Study. A workforce reduction has been implemented to prioritize resources. Despite challenges, seralutinib is considered an active treatment for advanced pulmonary arterial hypertension.
Read more →GOSS▼ -8.7%on this news· ran to -21% by day 3
Seralutinib aumenta volumen arterial pulmonar y reduce remodelado vascular: análisis por TC con IA
The article discusses the positive effects of Seralutinib on pulmonary arterial volume and vascular remodeling. Utilizing AI for analysis, the findings indicate that Seralutinib may provide significant benefits for patients with pulmonary conditions. The results suggest a promising avenue for further research and development in this area.
Read more →GOSS▼ -8.7%on this news· ran to -21% by day 3
Seralutinib en HAP: explorando mecanismos de remodelado inverso versus vasodilatacion
The article discusses Seralutinib's role in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It explores the mechanisms of reverse remodeling versus vasodilation in the treatment of these conditions. The content appears to be informational without specific outcomes or data presented.
Read more →GOSS▼ -8.7%on this news· ran to -21% by day 3
Seralutinib disminuye la producción de endotrofina (PRO-C6), un mediador de fibrosis e inflamación
Seralutinib has been shown to decrease the production of endotrophin (PRO-C6), which plays a significant role in fibrosis and inflammation. This reduction could have positive implications for patients suffering from conditions associated with these processes. The findings suggest a potential therapeutic benefit of Seralutinib in managing related diseases.
Read more →GOSS▼ -8.7%on this news· ran to -21% by day 3
Seralutinib preserva función pulmonar y actividad antifibrótica en modelos de fibrosis pulmonar
The article discusses the positive effects of Seralutinib in preserving lung function and exhibiting antifibrotic activity in models of pulmonary fibrosis. This suggests potential therapeutic benefits for patients suffering from related conditions. The findings highlight the drug's relevance in treating pulmonary arterial hypertension and pulmonary fibrosis.
Read more →GOSS▼ -8.7%on this news· ran to -21% by day 3
Seralutinib: efectos antifibróticos significativos y evidencia de modelos derivados de pacientes
The article discusses the significant antifibrotic effects of Seralutinib, highlighting evidence derived from patient models. This suggests a promising potential for the drug in treating conditions associated with fibrosis. The findings may have implications for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read more →GOSSGossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
Gossamer Bio's seralutinib failed to show significant improvement in a Phase 3 trial for pulmonary arterial hypertension, leading to an 80% drop in stock price. Despite some positive signals in high-risk patients, analysts express doubt about the drug's market viability. Gossamer plans to consult with the FDA regarding future steps, while suspending enrollment in another study.
Read more →GOSS▼ -80.1%on this newsshared move
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio announced topline results from the Phase 3 PROSERA Study of seralutinib for pulmonary arterial hypertension (PAH). Although the primary endpoint did not meet the stringent statistical threshold, seralutinib demonstrated significant improvements in six-minute walk distance (6MWD) and showed efficacy in high-risk patient subgroups. The company plans to discuss these results with the FDA for potential next steps.
Read more →GOSS▼ -5.8%on this news
Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
The article discusses the significant anti-fibrotic effects of Seralutinib, supported by evidence from patient-derived models. This finding suggests that Seralutinib may offer promising therapeutic benefits for conditions characterized by fibrosis. The research highlights the potential of this treatment in improving patient outcomes.
Read more →GOSS▼ -5.8%on this news
Seralutinib demonstrated in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
Seralutinib has shown in vitro effectiveness in reducing the vascular inflammatory drivers associated with pulmonary hypertension. This finding suggests that the drug may play a crucial role in managing this condition. The results could lead to improved treatment options for patients suffering from pulmonary hypertension.
Read more →GOSS▼ -5.1%on this newsshared move
Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics
The article discusses Seralutinib's targeting of fibrotic pathways in idiopathic pulmonary fibrosis (IPF), supported by evidence from single-cell transcriptomics. This research highlights the drug's potential to improve treatment outcomes for patients with pulmonary diseases. The findings suggest a promising avenue for further investigation and development in this therapeutic area.
Read more →GOSS▼ -5.1%on this newsshared move
Trial in progress: SERANATA, a phase 3 randomized, placebo-controlled trial to evaluate inhaled seralutinib for treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)
The SERANATA trial is a phase 3 randomized, placebo-controlled study evaluating inhaled seralutinib for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This trial aims to provide insights into the efficacy and safety of seralutinib, potentially offering a new therapeutic avenue for patients suffering from this condition. The study is currently in progress.
Read more →GOSS▼ -5.1%on this newsshared move
Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
The article discusses the effects of Seralutinib on endotrophin (PRO-C6) production, highlighting its potential to decrease this mediator of fibrosis and inflammation in an in vitro model of pulmonary fibrosis. This finding suggests that Seralutinib could be a promising candidate for treating pulmonary fibrosis. The results indicate a positive impact on managing fibrosis-related conditions.
Read more →GOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Gossamer Bio has announced the approval of stock option grants to three non-executive employees as part of its 2023 Employment Inducement Incentive Award Plan. The grants, effective January 5, 2026, allow for the purchase of up to 212,500 shares at an exercise price of $2.74 each. This initiative aims to attract and retain talent while supporting the company's focus on developing treatments for pulmonary hypertension.
Read more →GOSSMapping the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis
The article discusses a retrospective analysis of the diagnostic journey for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the U.S. It highlights the complexities and challenges faced by patients in obtaining a diagnosis. The analysis aims to provide insights into the healthcare process for these patients.
Read more →GOSSA Mixed Methods Analysis of Undertreatment and Delays in Therapy Escalation in Pulmonary Arterial Hypertension: Insights From a Real-world Patient Journey Study in the U.S.
The article discusses a mixed methods analysis focusing on the undertreatment and delays in therapy escalation for patients with Pulmonary Arterial Hypertension (PAH) in the U.S. It highlights insights from a real-world patient journey study, emphasizing the complexities faced by patients in receiving timely and adequate treatment. The findings aim to inform better management strategies for PAH.
Read more →GOSSSeralutinib Preserved Lung Function and Displayed Broad Anti-Fibrotic Activity in Models of Pulmonary Fibrosis
The article discusses the positive effects of Seralutinib in preserving lung function and its broad anti-fibrotic activity in models of pulmonary fibrosis. These findings suggest that Seralutinib may offer significant therapeutic benefits for patients suffering from this condition. The results highlight its potential role in managing pulmonary fibrosis effectively.
Read more →GOSSGossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study
Gossamer Bio reported its financial results for Q3 2025, highlighting a cash position of $180 million and the activation of the first site for its Phase 3 SERANATA study in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company anticipates topline results from the ongoing PROSERA Phase 3 study by February 2026. Despite the positive developments, Gossamer recorded a net loss of $48.2 million for the quarter, raising concerns over rising research and development expenses. The firm emphasizes its commitment to addressing unmet medical needs in pulmonary hypertension, supported by ongoing collaborations and community engagement.
Read more →GOSSPlease visit again. “Live at Congress” is currently under construction. While we work to add content, we invite you to browse and explore other sections of our website. Thank you for your patience! The Gossamer Bio Team.
Gossamer Bio has announced that their 'Live at Congress' section is under construction, inviting users to explore other areas of their website in the meantime. The message indicates a lack of available content and does not provide a timeline for when the section will be operational. This may lead to frustration among users seeking updates.
Read more →GOSS▼ -6.7%on this newsshared move
Seralutinib reduces vessel wall volume and increases small pulmonary artery vessel volume: Insights from AI-driven CT imaging analysis
The article discusses the positive effects of Seralutinib on pulmonary artery health, highlighting its ability to reduce vessel wall volume and increase the volume of small pulmonary arteries. These findings are supported by AI-driven CT imaging analysis, suggesting a significant advancement in the treatment of pulmonary arterial hypertension (PAH). The results indicate potential benefits for patients suffering from related conditions.
Read more →GOSSSeralutinib demonstrates in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
Seralutinib has demonstrated an ability to reduce vascular inflammatory drivers associated with pulmonary hypertension in vitro. This finding suggests that Seralutinib may offer a promising therapeutic avenue for patients suffering from this condition. The results could pave the way for further research and potential clinical applications.
Read more →GOSSSupplement to: Best practices for managing cough in PAH patients receiving inhaled therapies
The article serves as a supplement discussing best practices for managing cough in patients with pulmonary arterial hypertension (PAH) who are receiving inhaled therapies. It provides an overview of Seralutinib and related patient management strategies. The content is aimed at healthcare professionals and stakeholders involved in PAH treatment.
Read more →GOSSSeralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study
The article discusses the TORREY open-label extension study of Seralutinib, a treatment for pulmonary arterial hypertension (PAH) in adults. It highlights the potential benefits of Seralutinib for patients suffering from this condition. The study aims to gather long-term data on the efficacy and safety of the treatment.
Read more →GOSSGossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SER
Gossamer Bio announced its financial results for Q2 2025, reporting a net loss of $38.3 million, influenced by decreased collaboration revenue. The company has $213 million in cash, allowing it to fund operations into 2027. They are collaborating with Chiesi Group on the development of seralutinib, a potential treatment for PAH and PH-ILD, with clinical milestones approaching. Topline results from the Phase 3 PROSERA Study are expected in February 2026, alongside the first site activations for the SERANATA Study planned for Q4 2025.
Read more →GOSSBeneficio sostenido del tratamiento con seralutinib: un análisis post-hoc del estudio de extensión abierta TORREY
The article discusses the sustained benefits of seralutinib treatment based on a post-hoc analysis of the open-label TORREY extension study. This analysis highlights the promising results associated with the drug, indicating its potential effectiveness in treating conditions like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings contribute to the growing body of evidence supporting seralutinib's use.
Read more →GOSSLos modelos preclínicos respaldan el potencial sinérgico del seralutinib y el sotatercept en el tratamiento de la hipertensión arterial pulmonar
Preclinical studies indicate that seralutinib and sotatercept may work synergistically in treating pulmonary arterial hypertension (PAH). This combination could enhance therapeutic outcomes, offering new hope for patients suffering from this condition. The findings underscore the importance of continued research in developing effective treatments for PAH.
Read more →GOSSEfecto sostenido del seralutinib sobre biomarcadores circulantes en el estudio de extensión de etiqueta abierta de la fase 2 TORREY
The article discusses the sustained effects of seralutinib on circulating biomarkers in the open-label extension study of Phase 2 TORREY. This study highlights the potential benefits of seralutinib for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings suggest a promising avenue for further research and development.
Read more →GOSSGossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcem
Gossamer Bio has announced the completion of patient enrollment for the Phase 3 PROSERA Study, aimed at evaluating seralutinib in patients with pulmonary arterial hypertension (PAH). The study is designed to assess the effectiveness of seralutinib over a 48-week trial period, focusing on improvements in six-minute walk distance. Results from this registrational trial are expected to be released in February 2026. The study's patient selection criteria were informed by prior research, improving the chances of demonstrating a clinically significant benefit.
Read more →GOSSSeralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation
The article discusses Seralutinib, a drug being explored for its mechanisms in treating Pulmonary Arterial Hypertension (PAH). It focuses on comparing reverse remodeling and vasodilation effects of the drug. The content primarily serves as an overview of the drug and its implications for patients and investors.
Read more →GOSSGossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Enrollment Completion for Ongoing Registrational PROSERA Pha
Gossamer Bio announced its Q1 2025 financial results and updated on its clinical trials. The company closed new patient screening for the PROSERA Phase 3 Study in pulmonary arterial hypertension (PAH), with enrollment completion expected by early June 2025. Topline results from this pivotal study are anticipated in February 2026. Furthermore, Gossamer plans to initiate the Phase 3 SERANATA Study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) by the fourth quarter of 2025, supported by solid financial backing totaling approximately $258 million.
Read more →GOSS▼ -7.9%on this news
Trial in progress: PROSERA, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension
The PROSERA trial is a Phase 3 study evaluating the efficacy and safety of seralutinib in adults suffering from pulmonary arterial hypertension (PAH). This study aims to provide crucial data that could support the therapeutic use of seralutinib in this patient population, addressing a significant medical need.
Read more →GOSSGossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in P
Gossamer Bio announced its fourth quarter and full-year 2024 financial results, highlighting significant progress on its lead asset, seralutinib, for pulmonary arterial hypertension (PAH). The company intends to present topline data from the PROSERA Phase 3 trial by Q4 2025, and is preparing to initiate a second Phase 3 study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the latter half of 2025. Gossamer's financial position remains stable, with cash reserves expected to cover operations into 2027. Furthermore, seralutinib has received Orphan Drug Designation in Japan, opening avenues for market potential.
Read more →GOSSSustained effect of seralutinib on circulating biomarkers in the TORREY phase 2 open-label extension study
The TORREY phase 2 open-label extension study demonstrates that seralutinib has a sustained effect on circulating biomarkers. This finding suggests that seralutinib may offer continued benefits for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The results could enhance treatment strategies in these areas.
Read more →GOSSSustained benefit with seralutinib treatment: A post-hoc analysis of the TORREY open-label extension
The article discusses a post-hoc analysis of the TORREY open-label extension, highlighting the sustained benefits of seralutinib treatment. This analysis suggests that seralutinib may offer significant advantages for patients, particularly in the context of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings contribute to the understanding of seralutinib's long-term efficacy.
Read more →GOSSPreclinical models support the synergistic potential of seralutinib and sotatercept in treating pulmonary arterial hypertension
Recent preclinical studies indicate that the combination of seralutinib and sotatercept may have synergistic effects in treating pulmonary arterial hypertension (PAH). These findings suggest that the dual therapy could enhance treatment efficacy and improve patient outcomes. Further research is needed to validate these results in clinical settings.
Read more →GOSS▲ +27.7%on this news
A retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension (PAH) In the US
The article discusses a retrospective study on the real-world application of monotherapy for pulmonary arterial hypertension (PAH) in the United States. This research aims to shed light on treatment patterns and outcomes for PAH patients. The findings could inform future treatment strategies and improve patient care.
Read more →GOSS▲ +27.7%on this newsshared move
Best practices for managing cough in PAH patients receiving inhaled therapies
The article discusses best practices for managing cough in patients with pulmonary arterial hypertension (PAH) who are receiving inhaled therapies. It highlights the importance of effective management strategies to enhance patient care. The focus is on optimizing treatment approaches to mitigate cough symptoms associated with PAH.
Read more →GOSSReverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells
The article discusses the positive effects of seralutinib on pulmonary artery smooth muscle cells and precision-cut lung slices in the context of pulmonary arterial hypertension (PAH). It highlights seralutinib's ability to reverse remodeling and its anti-proliferative properties, suggesting potential benefits for patients with PAH. This research may lead to improved treatment strategies for this condition.
Read more →GOSSTrial in progress: Prosera, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension
The Prosera trial is a Phase 3 study evaluating the efficacy and safety of seralutinib in adults diagnosed with pulmonary arterial hypertension (PAH). This advanced stage of clinical testing aims to provide crucial data on the treatment's effectiveness. The study reflects a commitment to improving patient outcomes in this challenging condition.
Read more →GOSSSeralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension: Results of the Torrey phase 2 imaging substudy
The article discusses the positive results of Seralutinib in improving pulmonary arterial blood vessel volume distribution in patients with pulmonary arterial hypertension. These findings are derived from the Torrey phase 2 imaging substudy, indicating the drug's potential effectiveness in treating this condition. The study's outcomes may lead to enhanced treatment strategies for patients suffering from pulmonary arterial hypertension.
Read more →GOSSInterim results from the phase 1B and phase 2 Torrey open-label extension study of seralutinib in pulmonary arterial hypertension
The interim results from the phase 1B and phase 2 Torrey open-label extension study indicate that seralutinib may be effective in treating pulmonary arterial hypertension (PAH). The study is ongoing and aims to evaluate the drug's safety and efficacy. These findings could lead to improved treatment options for patients suffering from PAH.
Read more →GOSSSustained effect of seralutinib on circulating biomarkers in the Torrey phase 2 open-label extension study
The Torrey phase 2 open-label extension study demonstrated that seralutinib has a sustained effect on circulating biomarkers. This finding suggests that seralutinib may provide long-term benefits for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The results are promising for future treatment strategies.
Read more →GOSSSustained benefit with seralutinib treatment: A post-hoc analysis of the Torrey open-label extension
The article discusses a post-hoc analysis of the Torrey open-label extension, highlighting the sustained benefits of seralutinib treatment. This analysis suggests that seralutinib may offer long-term efficacy for patients. The findings are significant for those suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read more →GOSSGossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - $327 Million in Cash, Cash Equivalents Marketable Securities, as of
Gossamer Bio (Nasdaq: GOSS) announced its third-quarter 2024 financial results, reporting a cash reserve of $327 million, which will support operations into 2027. The CEO indicated that 2025 would be pivotal, with expectations for key Phase 3 trial results for seralutinib in pulmonary arterial hypertension (PAH) and the start of a Phase 3 study in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Despite a continued net loss of $30.8 million, the company showed progress with revenues from collaborations increasing to $9.5 million, up from zero in the prior year.
Read more →GOSSCurrent treatment patterns in pulmonary arterial hypertension (PAH): Real-world data from a contemporary U.S. Physician survey
The article discusses current treatment patterns for pulmonary arterial hypertension (PAH) based on a survey of U.S. physicians. It highlights the use of Seralutinib and its relevance in treating PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The survey aims to provide insights into real-world treatment approaches.
Read more →GOSSSeralutinib exhibits anti-fibrotic effects in human models of pulmonary fibrosis: an emerging option for group 1 and 3 pulmonary hypertension?
The article discusses Seralutinib's anti-fibrotic effects observed in human models of pulmonary fibrosis. It highlights the drug's potential as a treatment option for patients with group 1 and 3 pulmonary hypertension. The findings suggest that Seralutinib may offer new hope in managing these conditions.
Read more →GOSSSustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension
The article discusses a post-hoc analysis of the TORREY open-label extension, highlighting the sustained benefits of seralutinib treatment. This analysis suggests that seralutinib may offer long-term efficacy for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings contribute to understanding the treatment's impact on patient outcomes.
Read more →GOSSSustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study
The article discusses the sustained effects of seralutinib on circulating biomarkers as observed in the TORREY phase 2 open-label extension study. This research highlights the drug's potential benefits for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings suggest a promising avenue for ongoing treatment strategies.
Read more →GOSSPROSERA Study
The PROSERA study is a phase 3 clinical trial evaluating seralutinib for adults with Pulmonary Arterial Hypertension (PAH). This research aims to assess the drug's effectiveness and safety in treating this condition. The study is part of ongoing efforts to improve treatment options for PAH patients.
Read more →GOSSOpen-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
The PROSERA-EXT study aims to assess the long-term safety, tolerability, and efficacy of seralutinib in adults who have previously participated in seralutinib trials. This open-label extension provides an opportunity to gather additional data on the treatment's effects over an extended period. The study is listed on clinicaltrials.gov for further information.
Read more →GOSSTORREY Study
The TORREY study has been completed, revealing that Gossamer Bio's seralutinib (GB002) significantly improved hemodynamics, right heart structure, and function. The topline data, reported in December 2022, also indicated positive changes in biomarkers associated with pulmonary arterial hypertension (PAH) severity. These findings suggest potential benefits for patients with PAH.
Read more →GOSSOpen-label Extension Study of Seralutinib in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
An open-label extension study is set to assess the long-term effects of seralutinib in adults with pulmonary arterial hypertension (PAH). This study will involve subjects who have previously participated in seralutinib trials, aiming to gather further insights into the drug's efficacy and safety over an extended period.
Read more →GOSSA retrospective study investigating the real-world use of monotherapy in pulmonary arterial hypertension in the US
The article discusses a retrospective study focused on the real-world application of monotherapy for pulmonary arterial hypertension (PAH) in the United States. It outlines the context and significance of the study but does not provide specific findings or conclusions. The article serves as an overview of the study's objectives and relevance in the field of PAH treatment.
Read more →GOSSInterim Results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib in Pulmonary Arterial Hypertension
The article discusses interim results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib, a treatment for Pulmonary Arterial Hypertension (PAH). The study aims to evaluate the efficacy and safety of Seralutinib in patients. Positive interim results indicate potential benefits for patients suffering from this condition.
Read more →GOSSThe Clinical Development of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension
The article discusses the clinical development of inhaled Seralutinib, a treatment for pulmonary arterial hypertension (PAH). It outlines the objectives and potential benefits of the therapy, emphasizing its innovative delivery method. The development aims to enhance patient access and improve treatment outcomes for those suffering from PAH.
Read more →GOSSPROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
The PROSERA study is a Phase 3 clinical trial evaluating the efficacy and safety of Seralutinib in adults diagnosed with Pulmonary Arterial Hypertension (PAH). This trial represents a significant step in the development of new treatment options for this serious condition. The study aims to provide critical data that could influence future therapeutic strategies.
Read more →GOSSGossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update - $354 Million in Cash, Cash Equivalents Marketable Securities, as of
Gossamer Bio, a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2024, showcasing a net income of $49.2 million, a stark improvement from a loss in the same quarter last year. The company emphasized ongoing enrollment in the Phase 3 PROSERA Study for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). Gossamer also disclosed a strategic collaboration with Chiesi Group to co-commercialize seralutinib, enhancing its market potential. With $354 million in cash and equivalents, Gossamer is well-funded for operations through at least mid-2027.
Read more →GOSSSeralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
The article discusses a phase 2 trial named TORREY, which evaluates Seralutinib in adults suffering from pulmonary arterial hypertension (PAH). This trial is designed as a randomized, double-blind, placebo-controlled study, ensuring a high level of scientific rigor. The focus on PAH highlights the need for effective treatments in this area.
Read more →GOSS▲ +5.2%on this news· ran to +20% by day 3
Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
The article discusses the PROSERA trial, a Phase 3 study evaluating the efficacy and safety of Seralutinib in adults with Pulmonary Arterial Hypertension (PAH). This study represents a critical step in the development of Seralutinib as a treatment option for patients suffering from this condition. The trial aims to provide vital data that could influence future treatment protocols.
Read more →GOSS▲ +5.2%on this news· ran to +20% by day 3
Effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in pulmonary arterial hypertension
The article discusses the effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). It highlights the potential benefits of seralutinib as a treatment option, emphasizing its relevance in improving patient outcomes. The findings may contribute to advancing therapeutic strategies for PAH.
Read more →GOSS▲ +5.2%on this news· ran to +20% by day 3
Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension
The interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib indicate positive outcomes for patients with pulmonary arterial hypertension. The study's comprehensive approach, combining both phases, highlights the potential effectiveness of seralutinib. These findings may pave the way for further developments in treatment options for this condition.
Read more →GOSS▲ +5.2%on this news· ran to +20% by day 3shared move
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension: Results of the TORREY Phase 2 imaging substudy
The TORREY Phase 2 imaging substudy has shown that Seralutinib significantly improves the distribution of pulmonary arterial blood vessel volume in patients with pulmonary arterial hypertension (PAH). This positive outcome suggests that Seralutinib may offer new therapeutic benefits for PAH patients. The findings contribute to the growing body of evidence supporting Seralutinib's efficacy.
Read more →GOSS▲ +5.2%on this news· ran to +20% by day 3shared move
TORREY phase 2 study of seralutinib in pulmonary arterial hypertension: Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
The TORREY phase 2 study of seralutinib demonstrates positive results in patients with pulmonary arterial hypertension (PAH). The treatment led to improvements in circulating biomarkers associated with proliferation, inflammation, and fibrosis. These findings suggest that seralutinib may be an effective therapeutic option for managing PAH.
Read more →GOSSCardiac effort is less variable than six-minute walk distance, correlates with hemodynamics and is consistent with REVEAL 2.0 risk score in a sub-study of the TORREY phase 2 PAH trial
A sub-study of the TORREY phase 2 PAH trial indicates that cardiac effort is more consistent than the six-minute walk distance. This finding correlates with hemodynamic data and is consistent with the REVEAL 2.0 risk score. The results suggest that cardiac effort may be a reliable measure in assessing patients with pulmonary arterial hypertension (PAH).
Read more →GOSSTORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
The TORREY phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH) has shown promising results, with improvements in circulating biomarkers associated with proliferation, inflammation, and fibrosis. This suggests that seralutinib may be an effective treatment option for PAH. The study highlights the importance of monitoring these biomarkers during treatment.
Read more →GOSSInterim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension (PAH)
The interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension (PAH) suggest promising efficacy. This study is significant as it addresses a vital need in the treatment landscape for PAH. The combination of data from both phases strengthens the findings.
Read more →GOSS▼ -6.3%on this news
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update - Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected t
Gossamer Bio reported its financial results for Q1 2024, highlighting a transformative collaboration with Chiesi that adds $160 million to its balance sheet. The company is advancing its seralutinib drug development with ongoing Phase 3 trials in pulmonary arterial hypertension (PAH) and plans for a Phase 3 trial in pulmonary hypertension with interstitial lung disease (PH-ILD) set to begin in mid-2025. Cash reserves are solid, at $396 million, although the company reported a net loss of $41.9 million for the quarter, reflecting ongoing operational costs and investments in research and development.
Read more →GOSS▲ +5.5%on this newsshared move
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD Other Indications - Gossamer to receive $160 million development reimbursement payment an
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize seralutinib for pulmonary hypertension conditions. Gossamer will receive $160 million in development reimbursement and has the potential to earn up to $326 million in regulatory and sales milestones. The collaboration will enable both companies to leverage their respective expertise in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). A Phase 3 trial for seralutinib in PH-ILD is set to begin in mid-2025.
Read more →GOSSDocument Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio, Inc. has appointed Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors to enhance its strategic capabilities. Dr. Nathan, known for his expertise in pulmonary diseases, will guide the clinical development of seralutinib, particularly in addressing the unmet needs of pulmonary hypertension associated with interstitial lung disease. Meanwhile, Ms. Drynan brings significant financial and biotechnology industry experience, which is expected to bolster Gossamer's market position and financial management. These appointments are viewed as pivotal in the company’s efforts to improve treatment options for patients suffering from pulmonary hypertension.
Read more →GOSSGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA
Gossamer Bio has announced its financial results for the fourth quarter and full year of 2023, alongside a significant update regarding its clinical progress. The company reported the first patient dosed in its Phase 3 PROSERA Study for pulmonary arterial hypertension (PAH) and noted the acceptance of its protocol by Japan's PMDA, allowing local patient inclusion in the trial. Gossamer maintains a strong financial position with significant cash reserves to support ongoing operations, despite reporting substantial losses. The trial's outcome is critical for potential market entry in Japan and further development of seralutinib for PAH and related conditions.
Read more →GOSS▲ +6.3%on this news
Effects of inhaled Seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
The article discusses the effects of inhaled Seralutinib on right ventricular-pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). The findings suggest that Seralutinib may improve these cardiovascular parameters, indicating its potential as a therapeutic option for PAH. Further studies may be needed to confirm these results.
Read more →GOSS▲ +6.3%on this news
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging sub-study
The article discusses the positive results of Seralutinib in improving pulmonary arterial blood vessel volume distribution in patients with pulmonary arterial hypertension (PAH). These findings are based on the TORREY Phase 2 imaging sub-study, which highlights the potential therapeutic benefits of Seralutinib for PAH patients. The results may pave the way for further research and development in this area.
Read more →GOSSUnderstanding Drivers and Barriers to Participation in Clinical Trials for Patients with Pulmonary Arterial Hypertension (PAH)
The article discusses the factors influencing participation in clinical trials for patients with Pulmonary Arterial Hypertension (PAH). It highlights the importance of understanding both the drivers and barriers that affect patient enrollment in these studies. The content appears to be informative but lacks specific details on findings or conclusions.
Read more →GOSS▲ +5.7%on this news· ran to +39% by day 3
John Quisel
Dr. John Quisel has been the President and CEO of Disc Medicine since January 2020, leading the company to develop a diverse portfolio of hematology programs. Previously, he served as Executive Vice President at Acceleron Pharma, where he was instrumental in the company's growth and the acquisition by Merck & Co. for over $11 billion. Dr. Quisel has a strong academic background with degrees from Harvard, Stanford, and MIT.
Read more →GOSSDocument Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio, a clinical-stage biopharmaceutical company, announced the appointment of Dr. John Quisel, J.D., Ph.D., to its Board of Directors. Dr. Quisel, currently the President and CEO of Disc Medicine, has a strong background in pulmonary arterial hypertension (PAH) and previously held pivotal roles in Acceleron Pharma. His extensive experience and strategic insights are expected to benefit Gossamer's mission in developing seralutinib for PAH treatment. The company views his addition as a key enhancement to their leadership team.
Read more →GOSS▼ -7.6%on this news
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update - Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-
Gossamer Bio reported positive progress in its Phase 3 PROSERA Study for seralutinib, with site activations ahead of schedule. The company also has a solid cash position of $329 million, sufficient to fund operations into mid-2026. The upcoming data from the TORREY Open-Label Extension study is anticipated within Q4 2023. However, despite a reduced net loss compared to the previous year, uncertainties related to clinical outcomes and regulatory approvals remain.
Read more →GOSSSeralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy
The TORREY Phase 2 Imaging Substudy has demonstrated that Seralutinib improves pulmonary arterial blood vessel volume distribution in patients with pulmonary arterial hypertension (PAH). These findings suggest a potential benefit for patients suffering from this condition, highlighting the drug's efficacy in enhancing vascular health. The results may pave the way for further advancements in PAH treatment.
Read more →GOSSEffects of Inhaled Seralutinib on Right Ventricular-Pulmonary Arterial (RV-PA) Coupling and Right Heart Function in Pulmonary Arterial Hypertension (PAH)
The article discusses the effects of inhaled Seralutinib on right ventricular-pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). It provides an overview of the drug's potential benefits in improving heart function in this patient population. Further details on the study's findings and implications are not provided.
Read more →GOSSSeralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial
The article discusses the results of the Phase 2 TORREY Trial for Seralutinib, a treatment for Pulmonary Arterial Hypertension (PAH). The trial's findings indicate potential benefits of Seralutinib in managing this condition. The results are seen as a positive step forward in PAH treatment options.
Read more →GOSSSeralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging substudy
The article discusses the positive results of Seralutinib in improving pulmonary arterial blood vessel volume distribution in patients with pulmonary arterial hypertension (PAH). These findings are part of the TORREY Phase 2 imaging substudy, indicating potential advancements in PAH treatment. The results may enhance the understanding and management of this condition.
Read more →GOSSEffects of Inhaled Seralutinib on Right Ventricular Pulmonary Arterial Coupling and Right Heart Function in Pulmonary Arterial Hypertension
The article discusses the effects of inhaled Seralutinib on right ventricular pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). It highlights the potential benefits of this treatment approach, emphasizing its relevance in improving patient outcomes. The findings contribute valuable insights into managing PAH effectively.
Read more →GOSSPharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
The article discusses Seralutinib's pharmacology and its rationale for treating pulmonary arterial hypertension (PAH). It emphasizes the drug's potential benefits for patients suffering from PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The content suggests a positive outlook on Seralutinib's efficacy in clinical settings.
Read more →GOSS▼ -5.4%on this newsshared move
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extens
Gossamer Bio recently announced its financial results for Q2 2023, highlighting a significant cash position of $374 million following a recent private placement. The company is set to initiate a Phase 3 clinical trial for seralutinib in pulmonary arterial hypertension (PAH) patients in the third quarter of 2023, which represents a critical advancement in their business strategy. Additionally, Gossamer expects to release further data from its ongoing TORREY open-label extension study in PAH patients by late 2023 or early 2024. Despite the optimistic outlook, the company reported a net loss of $42.5 million for the quarter, although this figure showed improvement compared to the previous year.
Read more →GOSS▼ -31.9%on this news
For Investors and Media Bryan Giraudo, Chief Operating Officer and Chief Financial Officer Gossamer Bio Investor Relations ir gossamerbio.com
Gossamer Bio announced a $212 million private placement financing to support the ongoing development of seralutinib for pulmonary arterial hypertension. The financing included contributions from a range of institutional investors. The company also disclosed interim data from its TORREY study and plans to conduct a PROSERA Phase 3 trial, with a conference call scheduled to discuss this with domain experts. The private placement is set to close on July 24, 2023, subject to usual closing conditions.
Read more →GOSSGossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study -
Gossamer Bio reported its first quarter 2023 financial results and highlighted progress in its clinical development of seralutinib, following positive results from the Phase 2 TORREY study. The company received favorable feedback from the FDA and EMA regarding the registrational program for seralutinib, with a Phase 3 trial expected to start in Q3 2023. Despite a significant restructuring that led to a reduction in workforce, Gossamer maintains a strong financial position with $202 million in cash and equivalents, expected to fund operations for the next 12 months. The company emphasizes its commitment to advancing seralutinib for patients with pulmonary arterial hypertension, while other product candidates are being deprioritized.
Read more →GOSS▼ -8.5%on this news
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received Expected to Commence in the Second Half of 2023 - - To
Gossamer Bio has released its financial results for Q4 and the full year of 2022, alongside updates on its clinical trials. The company received FDA feedback and expects to initiate a Phase 3 clinical trial for seralutinib in the second half of 2023, with topline results from the ongoing TORREY study's extension anticipated in mid-2023. However, Gossamer has paused enrollment for the GB5121 trial due to a reassessment of resource allocation and risk. The company reported cash reserves of $256 million, sufficient for operations through the latter half of 2024, despite ongoing net losses.
Read more →GOSSGossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 milli
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 million in cash, cash equivalents marketable securities, as of
Read more →GOSSGossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penet
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update - Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patient in Phase 1b 2 STAR CNS Stu
Read more →GOSS▲ +31.9%on this news· ran to +56% by day 3
Gossamer Bio Announces $120 million Private Placement Financing
Gossamer Bio Announces $120 million Private Placement Financing SAN DIEGO - July 13, 2022 - Gossamer Bio, Inc. (Nasdaq GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunol
Read more →GOSS▲ +11.7%on this news· ran to +34% by day 3
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update - Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expect
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update - Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 - - Cash, cash equivalen
Read more →GOSSGossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update - GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update - GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topline results for the Phase 2 T
Read more →GOSSGossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due t
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays - - Phase 2 SHIFT-UC Study of GB
Read more →GOSS▲ +6.5%on this news
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline GB5121 GB7208 SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline GB5121 GB7208 SAN DIEGO - (BUSINESS WIRE) - October 11, 2021 - Gossamer Bio, Inc. (Nasdaq GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, de
Read more →GOSS▲ +10.6%on this news
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role SAN DIEGO - (BUSINESS WIRE) - September 21, 2021 - Gossamer Bio, Inc. (Nasdaq GOSS), a clinical-stage biopharmaceutical company focused on discovering, acq
Read more →GOSSGossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertensio
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Goss
Read more →GOSSDocument Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors SAN DIEGO - (BUSINESS WIRE) - June 14, 2021 - Gossamer Bio, Inc. (Nasdaq GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializi
Read more →GOSSGossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hy
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update - Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively
Read more →GOSSGossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer SAN DIEGO - (BUSINESS WIRE)
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer SAN DIEGO - (BUSINESS WIRE) - April 20, 2021 - Gossamer Bio, Inc. (Nasdaq GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring,
Read more →GOSSGossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update - Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update - Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colit
Read more →GOSSGossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004 SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002 TORREY Phase 2 trial activated in
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004 SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002 TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) - - G
Read more →GOSSGossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis - Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging fro
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis - Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups - - Statis
Read more →GOSSGossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update - GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in t
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update - GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB002: Expected to commence Pha
Read more →GOSSGossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 SAN DIEGO-(BUSINESS WIRE)
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027 SAN DIEGO-(BUSINESS WIRE)- May 18, 2020 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing
Read more →GOSSGossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update - GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update - GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering
Read more →GOSSGossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update - Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update - Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 - - Cash, cash equivalents a
Read more →GOSSGossamer Bio Announces Third Quarter 2019 Financial Results - Clinical programs on track for multiple topline data releases in 2020 - - Entered clinical trial collaboration with Merck to evaluate KEYTRUDA (pembrolizumab)
Gossamer Bio Announces Third Quarter 2019 Financial Results - Clinical programs on track for multiple topline data releases in 2020 - - Entered clinical trial collaboration with Merck to evaluate KEYTRUDA (pembrolizumab) in combination with GB1275 in advanced solid tumors - -
Read more →GOSSGossamer Bio Announces Second Quarter 2019 Financial Results - Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types - - Five active clinical trials across four clinical programs, with data
Gossamer Bio Announces Second Quarter 2019 Financial Results - Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types - - Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 - - Comp
Read more →GOSSGossamer Bio Announces First Quarter 2019 Financial Results - Multiple trial initiations and data readouts expected in the next 12 months - - Company to host conference call today at 8:30 a.m. ET
Gossamer Bio Announces First Quarter 2019 Financial Results - Multiple trial initiations and data readouts expected in the next 12 months - - Company to host conference call today at 8:30 a.m. ET - SAN DIEGO, Calif., May 14, 2019 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical
Read more →GOSSGossamer Bio Secures Debt Facility for Up to $150 Million
Gossamer Bio Secures Debt Facility for Up to $150 Million SAN DIEGO, Calif., May 2, 2019 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunol
Read more →GOSSGossamer Bio Announces 2018 Annual Financial Results
Gossamer Bio Announces 2018 Annual Financial Results SAN DIEGO, Calif., March 22, 2019 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunolog
Read more →Competitive Position
How GOSS ranks across every disease it competes inCompetitive Position is a premium feature
See how GOSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial